Cracking the Code on Back Pain

In this episode of Med Tech Gurus, we welcome Neil Klompas, Chief Executive Officer of Augurex Life Sciences. With more than two decades of experience leading companies at the intersection of diagnostics, rheumatology, and translational medicine, Neil is pioneering a new era of autoimmune biomarker discovery. Under his leadership, Augurex developed SpineStat, the world's first blood test designed to identify axial spondyloarthritis (AxSpA)—a chronic inflammatory spinal disease that affects millions yet often goes undiagnosed for nearly a decade. By leveraging the anti-14-3-3η autoantibody in combination with CRP, SpineStat is helping clinicians detect disease earlier, prevent irreversible spinal damage, and even reduce opioid dependence through faster, targeted treatment. Neil shares how engaging early with regulators helped Augurex earn FDA Breakthrough Device Designation, why he believes rheumatology is poised for its "oncology moment," and how keeping his team centered on the patient journey drives innovation every day. If you're passionate about precision diagnostics, regulatory navigation, and building mission-driven teams, this episode is a masterclass in turning unmet medical need into measurable clinical impact.